Barclays PLC Grows Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO)

Barclays PLC grew its stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 141.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 126,675 shares of the company's stock after purchasing an additional 74,130 shares during the period. Barclays PLC owned approximately 0.29% of Soleno Therapeutics worth $5,694,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Corebridge Financial Inc. grew its position in Soleno Therapeutics by 2.9% in the fourth quarter. Corebridge Financial Inc. now owns 12,720 shares of the company's stock worth $572,000 after acquiring an additional 357 shares during the period. Summit Investment Advisors Inc. grew its holdings in shares of Soleno Therapeutics by 24.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 2,677 shares of the company's stock worth $120,000 after purchasing an additional 522 shares during the period. AlphaQuest LLC raised its holdings in Soleno Therapeutics by 1,154.4% in the 4th quarter. AlphaQuest LLC now owns 715 shares of the company's stock valued at $32,000 after buying an additional 658 shares during the period. US Bancorp DE acquired a new position in Soleno Therapeutics in the fourth quarter valued at about $34,000. Finally, Alliancebernstein L.P. boosted its stake in Soleno Therapeutics by 3.5% during the fourth quarter. Alliancebernstein L.P. now owns 23,810 shares of the company's stock worth $1,070,000 after buying an additional 800 shares during the period. 97.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on SLNO. UBS Group set a $105.00 price objective on shares of Soleno Therapeutics in a report on Thursday, March 27th. Lifesci Capital upgraded Soleno Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 4th. Guggenheim reaffirmed a "buy" rating and issued a $81.00 price objective (up from $70.00) on shares of Soleno Therapeutics in a research note on Friday, March 28th. Laidlaw increased their target price on Soleno Therapeutics from $75.00 to $105.00 and gave the stock a "buy" rating in a research note on Thursday, March 27th. Finally, Piper Sandler lifted their target price on Soleno Therapeutics from $93.00 to $145.00 and gave the company an "overweight" rating in a research report on Thursday, April 24th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $104.67.

Soleno Therapeutics Price Performance

Shares of Soleno Therapeutics stock traded down $0.08 on Wednesday, reaching $75.19. 353,724 shares of the company were exchanged, compared to its average volume of 727,185. Soleno Therapeutics, Inc. has a 1-year low of $36.93 and a 1-year high of $76.56. The company has a market cap of $3.75 billion, a P/E ratio of -22.65 and a beta of -2.29. The stock's 50 day moving average price is $58.49 and its 200-day moving average price is $53.16.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.41). On average, research analysts predict that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current fiscal year.

Insider Activity

In other Soleno Therapeutics news, VP Michael F. Huang sold 14,583 shares of the stock in a transaction that occurred on Thursday, March 27th. The shares were sold at an average price of $69.51, for a total value of $1,013,664.33. Following the transaction, the vice president now directly owns 36,817 shares in the company, valued at $2,559,149.67. This represents a 28.37 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Patricia C. Hirano sold 3,782 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $70.11, for a total transaction of $265,156.02. Following the sale, the insider now directly owns 27,036 shares in the company, valued at approximately $1,895,493.96. The trade was a 12.27 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 942,672 shares of company stock worth $64,058,781. 12.30% of the stock is currently owned by insiders.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.